Other recent studies have confirmed in a large series of PanNET patients that alternative lengthening of telomeres (ALT) and loss of DAXX/ATRX predict metastatic disease and poor survival in patients with PanNET [209,210]. This evidence concerns the gene ATRX and metastatic neoplasm.